NAMPT and neoplasm: In addition to the NAMPT mutations that have been identified preclinically as mediators of acquired resistance to NAMPT inhibitors, recurrent NAMPT mutations have been rarely (< 1%) described in patient tumor samples across multiple types of malignancies [Table 3][38,52-57].